SGMOQ·July 20, 2026·bankruptcy
Sangamo Therapeutics Receives Nasdaq Delisting Determination as Bankruptcy Sale Process Advances
Sangamo Therapeutics disclosed that Nasdaq denied its appeal to remain listed, and the bankruptcy court approved bidding procedures for the sale of the company's assets, setting an August 4 bid deadline and an August 20 sale hearing.